JP4994043B2 - ミトラタピデ経口用溶液 - Google Patents
ミトラタピデ経口用溶液 Download PDFInfo
- Publication number
- JP4994043B2 JP4994043B2 JP2006550163A JP2006550163A JP4994043B2 JP 4994043 B2 JP4994043 B2 JP 4994043B2 JP 2006550163 A JP2006550163 A JP 2006550163A JP 2006550163 A JP2006550163 A JP 2006550163A JP 4994043 B2 JP4994043 B2 JP 4994043B2
- Authority
- JP
- Japan
- Prior art keywords
- oral solution
- solution according
- polyethylene glycol
- pharmaceutically acceptable
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
−ミトラタピデ 5mg/ml
−ブチル化ヒドロキシアニソール(BHA) 2mg/ml
−スクラロース 2mg/ml
−PEG 400 1ml(適量)
を含有する。
Claims (12)
- ジメチルイソソルビド、ジエチレングリコールモノエチルエーテル、カプリロカプロイルマクロゴル−8グリセリド、プロピレングリコールモノラウレート、ポリエチレングリコール 200、ポリエチレングリコール 300、ポリエチレングリコール 400およびそれらの混合物、並びに400より高い平均分子量を有するポリエチレングリコール(PEGs)と400より低い平均分子量を有するPEGsの室温で溶液である混合物から成る群から選ばれる製薬学的に許容され得る溶媒中に、ミトラタピデ(mitratapide)又はその製薬学的に許容され得る塩、味感矯正剤及び酸化防止剤を含んでなる経口用溶液であって、22℃にて少なくとも5mg/mlのミトラタピデが溶解している溶液。
- 製薬学的に許容され得る溶媒がポリエチレングリコール 400である請求項1に記載の経口用溶液。
- 味感矯正剤が強力甘味料、バルク甘味料(bulk sweetener)、風味料又は味感隠蔽剤である請求項1または2に記載の経口用溶液。
- 味感矯正剤がサッカリン、アスパルテーム、アセスルフェーム、シクラミン酸塩、アリテーム、ジヒドロカルコン甘味料、モネリン、ネオヘスペリジン、ネオテーム、ステビオシド又はスクラロース(4,1’,6’−トリクロロ−4,1’,6’−トリデオキシガラクトスクロース)及び製薬学的に許容され得るそれらの塩より成る群から選ばれる強力甘味料である請求項3に記載の経口用溶液。
- 強力甘味料が0.1〜10mg/mlの範囲の量で存在する請求項4に記載の経口用溶液。
- 強力甘味料がスクラロースである請求項5に記載の経口用溶液。
- 酸化防止剤がBHA、BHT、没食子酸プロピル、DL−α−トコフェロール及びクエン酸ならびにそれらの混合物より成る群から選ばれる請求項1〜6のいずれかに記載の経口用溶液。
- 酸化防止剤が0.1〜10mg/mlの範囲の量で存在する請求項7に記載の経口用溶液。
- 酸化防止剤がBHAである請求項8に記載の経口用溶液。
- PEG 400中に溶解された5mg/mlのミトラタピデ、0.5〜5mg/mlの範囲の量のスクラロース及び1mg/ml〜5mg/mlの範囲の量のBHAを含んでなる請求項9に記載の経口用溶液。
- PEG 400中に溶解された5mg/mlのミトラタピデ、2mg/mlの量のスクラロース及び2mg/mlの量のBHAを含んでなる請求項10に記載の経口用溶液。
- ジメチルイソソルビド、ジエチレングリコールモノエチルエーテル、カプリロカプロイルマクロゴル−8グリセリド、プロピレングリコールモノラウレート、ポリエチレングリコール 200、ポリエチレングリコール 300、ポリエチレングリコール 400およびそれらの混合物、並びに400より高い平均分子量を有するポリエチレングリコール(PEGs)と400より低い平均分子量を有するPEGsの混合物より成る群から選ばれる製薬学的に許容され得る溶媒中に、ミトラタピデ、味感矯正剤及び酸化防止剤を溶解し、均一な溶液が得られるまで攪拌する段階を含んでなることを特徴とする請求項1〜11のいずれかに記載の経口用溶液の調製方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04100177.7 | 2004-01-21 | ||
EP04100177 | 2004-01-21 | ||
PCT/EP2005/050181 WO2005070390A2 (en) | 2004-01-21 | 2005-01-18 | Mitratapide oral solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007518774A JP2007518774A (ja) | 2007-07-12 |
JP4994043B2 true JP4994043B2 (ja) | 2012-08-08 |
Family
ID=34802664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006550163A Expired - Fee Related JP4994043B2 (ja) | 2004-01-21 | 2005-01-18 | ミトラタピデ経口用溶液 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080234291A1 (ja) |
EP (1) | EP1708680A2 (ja) |
JP (1) | JP4994043B2 (ja) |
AU (1) | AU2005205933B2 (ja) |
CA (1) | CA2552988A1 (ja) |
WO (1) | WO2005070390A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
US8940796B2 (en) | 2006-02-21 | 2015-01-27 | Wyeth Llc | Phenylephrine liquid formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
US20080107787A1 (en) * | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
WO2008090198A1 (en) * | 2007-01-25 | 2008-07-31 | Janssen Pharmaceutica Nv | Use of mtp inhibitors for increasing levels of satiety hormones |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
WO2016059219A1 (en) * | 2014-10-17 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100227231B1 (ko) * | 1994-10-27 | 1999-11-01 | 디르크 반테 | 아포리포프로테인-b 합성 억제제 |
EP1073424A1 (en) * | 1998-04-27 | 2001-02-07 | Janssen Pharmaceutica N.V. | Pellets having a core coated with a lipid lowering agent and a polymer |
EE200300201A (et) * | 2000-10-31 | 2003-08-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos |
JP2004522802A (ja) * | 2001-02-16 | 2004-07-29 | ラヴィファーム・ラボラトリーズ・インク | 水溶性で風味良い複合体 |
MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
-
2005
- 2005-01-18 EP EP05701534A patent/EP1708680A2/en not_active Withdrawn
- 2005-01-18 AU AU2005205933A patent/AU2005205933B2/en not_active Ceased
- 2005-01-18 WO PCT/EP2005/050181 patent/WO2005070390A2/en not_active Application Discontinuation
- 2005-01-18 CA CA002552988A patent/CA2552988A1/en not_active Abandoned
- 2005-01-18 JP JP2006550163A patent/JP4994043B2/ja not_active Expired - Fee Related
- 2005-01-18 US US10/585,754 patent/US20080234291A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2552988A1 (en) | 2005-08-04 |
AU2005205933A1 (en) | 2005-08-04 |
JP2007518774A (ja) | 2007-07-12 |
WO2005070390A2 (en) | 2005-08-04 |
US20080234291A1 (en) | 2008-09-25 |
EP1708680A2 (en) | 2006-10-11 |
AU2005205933B2 (en) | 2010-02-18 |
WO2005070390A3 (en) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4994043B2 (ja) | ミトラタピデ経口用溶液 | |
EP1824493B1 (en) | Oral suspension comprising meloxicam | |
KR101568681B1 (ko) | 안정화된 카리스바메이트 소아용 현탁액 | |
CN109568253B (zh) | 液体制剂 | |
CN101360487A (zh) | 液体剂型中含硫药物的药物制剂 | |
US10537523B2 (en) | Oral suspension comprising telmisartan | |
US20230263796A1 (en) | Pharmaceutical solution for oral dosage | |
EP2793857B1 (en) | Drug delivery technology | |
AU770073B2 (en) | Prucalopride oral solution | |
CN112370450A (zh) | 格拉匹纶组合物及其使用方法 | |
KR20210107038A (ko) | 브라나플람의 경구 제형 | |
US20210322345A1 (en) | Midodrine hydrochloride oral solution and uses thereof | |
US20230255885A1 (en) | Chemotherapeutic pharmaceutical suspension for oral dosage | |
EP2519261B1 (en) | Oral liquid pharmaceutical composition of nifedipine | |
KR20240006600A (ko) | 투약 요법 | |
CN117715623A (zh) | 恩杂鲁胺的新型口服液组合物及其制备方法 | |
GR20190100342A (el) | Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν χαμηλη συγκεντρωση υδροχλωρικης ρανιτιδινης καταλληλα για παιδιατρικη χρηση | |
US20220160698A1 (en) | Pharmaceutical oral liquid solution of ivacaftor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080116 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080116 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110804 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110815 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20111116 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111116 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111220 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20111220 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20111226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120424 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120508 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150518 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |